Pinoxin Phase 2 Trial for Radiation-Induced Skin Injury (NCT07545720)
Summary
A Phase 2 clinical trial (NCT07545720) evaluating Pinoxin for the prevention of radiation-induced skin injury in cancer patients undergoing radiotherapy was registered on April 22, 2026. Patients are randomized to receive either Pinoxin or placebo, with the primary endpoint being the rate of grade 2 or greater skin injury. This trial registration appears on ClinicalTrials.gov as an informational record of ongoing research, not a regulatory approval or mandate.
“The rate of grade 2 or greater skin injury will be analyzed.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
A new Phase 2 clinical trial registration for Pinoxin was added to ClinicalTrials.gov on April 22, 2026, under identifier NCT07545720. The trial will enroll cancer patients undergoing radiotherapy and randomly assign them to Pinoxin treatment or placebo, with the rate of grade 2 or greater radiation-induced skin injury as the primary outcome measure.
Affected parties—oncology drug developers, radiotherapy centers, and clinical investigators—should note this trial registration as informational only. It does not create compliance obligations, reporting duties, or regulatory approval requirements. Sponsors of competing skin protective agents or developers of combination radiotherapy products may wish to monitor trial results as the research progresses.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pinoxin for the Prevention of Radiation-Induced Skin Injury
Phase 2 NCT07545720 Kind: PHASE2 Apr 22, 2026
Abstract
The incidence of radiation-induced skin injury is high, and effective preventive measures are currently lacking. This study evaluates the role of the skin protective agent Pinoxin in preventing skin injury. Patients are randomly assigned into two prospective groups: treatment group and control group. In treatment group, patients will receive Pinoxin treatment. In control group，patients will receive placebo treatment. The rate of grade 2 or greater skin injury will be analyzed.
Conditions: Cancer Patients Undergoning Radiotherapy
Interventions: pinoxin, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.